Ai/E¹º® is a nano-molecular refined lacteal complex containing a vast array of naturally occurring molecules with a molecular weight of less than 100,000 Dalton. The presence and viability of specific molecules has been confirmed by application of measurement and assay technologies in the laboratory of Tufts University in Boston, MA and at Tiburon Labs in Tucson, AZ. Expression of certain molecules in Ai/E¹º® has been expanded by the application of patented and proprietary processes.
Each of the molecules has a unique purpose in supporting immune function and the following references have been arranged by molecule. This document does not include all the molecules present in Ai/E¹º®. Many have not yet been sequenced and studied.
Bateman A et al The effect of HP-1 and related neutrophil granule peptides on DNA synthesis in HL-60 cells. Regulatory Peptides 35: 135-143 (1991)
Bateman A et al The isolation and identification of multiple forms of the neutrophil granule peptides from human leukemic cells. Journal of Biological Chemistry 266: 75247530 (1991)
Boman HG Antibacterial peptides: key components needed in immunity. Cell 65: 205207 (1991)
Cullor JS et al Bactericidal potency and mechanistic specificity of neutrophil defensins against bovine mastitis pathogens. Vet. Microbiol. 29: 49-58 (1991)
Daher KA et al Isolation and characterization of human defensin cDNA clones. Proceedings of the National Academy of Science (USA) 85: 7327-7331 (1988)
Eisenhauer PB and Lehrer RI Mouse neutrophils lack defensins. Infection and Immunity 60: 3446-3447 (1992)
Eisenhauer PB et al Cryptdins: antimicrobial defensins of the murine small intestine. Infect. Immunology 60: 3556-3565 (1992)
Ganz T et al Defensins: microbicidal and cytotoxic peptides of mammalian host defense cells. Medical Microbiology and Immunology 181: 99-105 (1992)
Garcia JR et al Identification of a novel, multifunctional beta-defensin (human betadefensin 3) with specific antimicrobial activityIts interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell and Tissue Research 306(2): 257-64 (2001)
Gera JF and Lichtenstein A Human neutrophil peptide defensins induce single strand DNA breaks in target cells. Cellular Immunology 138: 108-120 (1991)
Harwig SS et al Characterization of defensin precursors in mature human neutrophils. Blood 79: 1532-1537 (1992)
Hill CP et al Crystal structure of defensin HNP-3, an amphiphilic dimer: mechanisms of membrane permeabilization. Science 251: 1481-1485 (1991)
Jones DE and Bevins CL Paneth cells of the human small intestine express an antimicrobial peptide gene. Journal of Biological Chemistry 267: 23216-23225 (1992);
Lehrer et al Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annual Review of Immunology 11: 105-128 (1993)
Lichtenstein A Mechanism of mammalian cell lysis mediated by peptide defensins. Evidence for an initial alteration of the plasma membrane. Journal of Clinical Investigation 88: 93-100 (1991)
Lin MY et al The defensin-related murine CRS1C gene: expression in Paneth cells and linkage to Defcr, the cryptdin locus. Genomics 14: 363-368 (1992)
Liu L et al The human beta-defensin-1 and alpha-defensins are encoded by adjacent genes: two peptide families with differing disulfide topology share a common ancestry. Genomics
43: 316-320 (1997)
Michaelson D et al Cationic defensins arise from charge-neutralized propeptides: a mechanism for avoiding leukocyte autocytotoxicity? Journal of Leukocyte Biology 51: 634-639 (1992)
Panyutich AV et al Human neutrophil defensin and serpins form complexes and inactivate each other. American Journal of Respir. Cell Mol. Biol. 12: 351-357 (1995);
Ouellette AJ and Lualdi JC A novel mouse gene family coding for cationic, cysteine-rich peptides. Regulation in small intestine and cells of myeloid origin. Journal of Biological Chemistry 265: 9831-9837 (1990)
Ouellette AJ et al Purification and primary structure of murine cryptdin-1, a Paneth cell Defensin. FEBS Letters 304: 146-148 (1992) Panyutich AV et al An enzyme immunoassay for human defensins Journal of Immunological Methods 141: 149-155 (1991)
Panyutich A and Ganz T Activated alpha 2-macroglobulin is a principal defensinbinding protein. American Journal of Respir. Cell. Mol. Biol. 5: 101-106 (1991);
Ouellette AJ and Lualdi JC A novel mouse gene family coding for cationic, cysteine-rich peptides: regulation in small intestine and cells of myeloid origin. Journal of Biological Chemistry 265: 9831-9837 (1990)
Selsted ME et al Enteric Defensins: antibiotic peptide components of intestinal host defense. Journal of Cell Biology 118: 929-936 (1992)
Sparkes RS et al Assignment of defensin gene(s) to human chromosome 8p23. Genomics 5: 240-244 (1989)
Territo MC et al Monocyte-chemotactic activity of defensins from human neutrophils. Journal of Clinical Investigation 84: 2017-2020 (1989)
Valore EV and Ganz T Posttranslational processing of defensins in immature human myeloid cells. Blood 79: 1538-1544 (1992)
Raj PA, Dentino AR. FEMS Microbiol Lett 2002 Jan 2;206(1):9-18 Current status of defensins and their role in innate and adaptive immunity.
Kluver E, Schulz A, Forssmann WG, Adermann K. J Pept Res 2002 Jun;59(6):241-8 Chemical synthesis of beta-defensins and LEAP-1/hepcidin.
Cullor JS et al Bactericidal potency and mechanistic specificity of neutrophil defensins against bovine mastitis pathogens. Vet. Microbiol. 29: 49-58 (1991).
Gera JF and Lichtenstein A Human neutrophil peptide defensins induce single strand DNA breaks in target cells. Cellular Immunology 138: 108-120 (1991). Liu AY, et. al. “Human (beta)-Defensin-2 Production in Keratinocytes is Regulated by Interleukin-1, Bacteria, and the State of Differentiation”, J Invest Dermatol 2002 Feb; 118(2): 275-281.
Kishi A, Takamori Y, Ogawa K, Takano S, Tomita S, Tanigawa M, Niman M, Kishida T, Fujita S. Differential expression of granulysin and perforin by NK cells in cancer patients and correlation of impaired granulysin expression with progression of cancer, Department of Microbiology, Kyoto Prefectural University of Medicine, Kyoto, 602-0841, Japan. Kishia@lpc-dns.louis-pasteur.or.jp,Cancer Immunol Immunother 2002 Jan;50(11):604-14 Persio JF and Abboud CN Activation of neutrophils by granulocyte-macrophage colony-stimulating factor. Immunology Ser. 57: 457-84 (1992)
Leippe M. Ancient weapons: NK-lysin, is a mammalian homolog to pore-forming peptides of a protozoan parasite, Cell 1995 Oct 6;83(1):17-8
Bruhn H, Leippe M. Comparative modeling of amoebapores and granulysin based on the NK-lysin structure-structural and functional implications, Biol Chem 1999 JulAug;380(7-8):1001-7
Worku S, Hoft DF. Differential effects of control and antigen-specific T cells on intracellular mycobacterial growth, Infect Immun 2003 Apr;71(4):1763-73
Hamamoto K, Kida Y, Zhang Y, Shimizu T, Kuwano K. Antimicrobial activity and stability to proteolysis of small linear cationic peptides with D-amino acid substitutions, Microbiol Immunol 2002;46(11):741-9
Granulysin crystal structure and a structure-derived lytic mechanism., J Mol Biol 2003 Jan 10;325(2):355-65
Sun Q, Burton RL, Lucas KG. Cytokine production and cytolytic mechanism of CD4(+) cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Barr virus-specific T-cell cultures, Blood 2002 May 1;99(9):3302-9
Dieli F, Sireci G, Caccamo N, Di Sano C, Titone L, Romano A, Di Carlo P, Barera A, Accardo-Palumbo A, Krensky AM, Salerno A. Selective depression of interferon-gamma and granulysin production with increase of proliferative response by Vgamma9/Vdelta2 T cells in children with tuberculosis, J Infect Dis 2002 Dec 15;186(12):1835-9
Canaday DH, Wilkinson RJ, Li Q, Harding CV, Silver RF, Boom WH. CD4(+) and CD8(+) T cells kill intracellular Mycobacterium tuberculosis by a perforin and Fas/Fas ligand-independent mechanism, J Immunol 2001 Sep 1;167(5):2734-42
Krensky AM. Granulysin: a novel antimicrobial peptide of cytolytic T lymphocytes and natural killer cells. Biochem Pharmacol 2000 Feb 15;59(4):317-20
Sugahara T et al The mode of actions of glyceraldehyde-3-phosphate dehydrogenase identified as an immunoglobulin production stimulating factor.FEBS Letters 368(1): 9296 (1995)
Sugahara T et al Immunoglobulin production stimulating factor-II alpha (IPSF-II alpha) is glyceraldehyde-3-phosphate dehydrogenase like protein. Cytotechnology 6(2): 115-120 (1991)
Sugahara T et al Purification and characterization of immunoglobulin production stimulating factor-II beta derived from Namalwa cells. Cytotechnology 10(2): 137-146 (1992)
Sugahara T et al Inhibition of immunoglobulin production stimulating activity of glyceraldehyde-3-phosphate dehydrogenase by nucleotides. Bioscience Biotechnology Biochemistry 62(6): 1237-9 (1998)
Sugahara T et al A novel function of enolase from rabbit muscle; an immunoglobulin production stimulating factor. Biochimica Biophysica Acta 1380(2): 163-76 (1998);
Sugahara T et al The mode of actions of lysozyme as an immunoglobulin production stimulating factor. Biochimica Biophysica Acta 1475(1): 27-34 (2000)
Toyoda T et al Purification and characterization of immunoglobulin production stimulating factor derived from human B lymphoblastoid HO-323 cells. Cytotechnology 3(2): 189-197 (1990)
Yamada K et al Partial purification and characterization of immunoglobulin production stimulating factor derived from Namalwa cells. In vitro Cellular and Developmental Biology
25: 243-247 (1989)
Nuijens JH, van Berkel PH, Schanbacher FL. Structure and biological actions of lactoferrin, J Mammary Gland Biol Neoplasia 1996 Jul; 1(3):285-95
Weinberg ED. Human lactoferrin: a novel therapeutic with broad spectrum potential, J Pharm Pharmacol 2001 Oct;53(10):1303-10
Tomita M, Wakabayashi H, Yamauchi K, Teraguchi S, Hayasawa H. Bovine lactoferrin and lactoferricin derived from milk: production and applications. Biochem Cell Biol 2002;80(1):109-12
Faurschou M, Sorensen O, Johnsen A, Askaa J, Borregaard N. Defensin-rich granules of human neutrophils: characterization of secretory properties BiochimBiophysActa 2002 Aug 19;1591(1-3):29
Agerberth B et al The human antimicrobial and chemotactic peptides LL-37 and alphadefensins are expressed by specific lymphocyte and monocyte populations. Blood 96(9): 3086-93 (2000)
Cowland JB et al hCAP-18, a cathelin/pro-bactenecin-like protein of human neutrophil specific granules. FEBS Letters 368: 173-176 (1995)
Frohm M et al The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. Journal of Biological Chemistry 272(24): 15258-63 (1997)
Gallo RL et al Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adulot mouse. Journal of Biological Chemistry. 272: 13088-93 (1997)
Gudmundsson GH et al The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. European Journal of Biochemistry 238: 325-332 (1996)
Harwig SS et al Prophenin-1, anexceptionally proline-rich antimicrobial peptide from porcine leukocytes. FEBS Letters 362: 65-69 (1995)
Johansson J et al Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. Journal of Biological Chemistry 273(6): 3718-24 (1998)
Kirikae T et al Protective effects of a human 18-kilodalton cationic antimicrobial protein (CAP18)-derived peptide against murine endotoxemia. Infection and Immunity 66: 18611868 (1998)
Migorodskaya OA et al Primary structure of three cationic peptides from porcine neutrophils. Sequence determination by the combined usage of electgrospray mass spectrometrty and Edman degradation. FEBS Letters 330: 339-342 (1993)
Nagaoka I et al Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14+ cells. Journal of Immunology 167: 3329-3338 (2001) Niyonsaba F et al A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology 106: 20-26 (2002)
Nizet V et al Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature (London) 414: 454-457 (2001)
Sorensen OE et al Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97: 3951-3959 (2001);
Sorensen O et al An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma Journal of Immunological Methods 206: 53-59 (1997)
Wang Y et al Apolipoprotein A1 binds and inhibits the human antibacterial/cytotoxic peptide LL-37. Journal of Biological Chemistry 273: 33115-18 (1998)
Zanetti M et al Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Letters 374: 1-5 (1995)
Lawrence HS, The cellular transfer of cutaneous hypersensitivity to tuberculin in man, Proc Soc Exp BioI med 1949. 71.516
Wilson, Paddock GV Process for obtaining transfer factor from colostrum transfer factor soobtained and useÊthereof. US Patent Number 4816563, Mar. 28,1989
Lawerence HS A new basis for the imniunoregulatory activities of transfer factor -- an arcane dialect in the language of cells., Horkowsky W. Cell Immunol 1983,82, 102-16.
Kirkpatrick CH Structural Nature and Function of Transfer Factors, Annals of the New York Academy of Sciences 1993, 685, 362-368.
Pizza G. Visa D, Bouchiex CI, Corrado F. Effect of in vitro produced transfer factor on the immune response of cancer patients. Eur J Cancer 1977, 13, 9 17-23.
Roda E, Visa D, Pizza G, Mastroroberto L, Phillips J, De Vinci c, Barbra L. Transfer factor for the treatment of HbsAg-positive chronic active hepatitis. Proc Soc Exp Med 1985, 178, 468-75.
Fudenberg HH, Pizza G. Transfer factor 1993 New Frontiers. Progress in drug Res. 1994, 42, 309400.
Lawerence HS. Borkowsky W Transfer factor - current status and future prospects.. Biotherapy 1996,9(1-3), 1-5.
Kirkpatrick CH Activities and characteristics of transfer factors.. Biotherapy 1996, 9, 13-6.
Marwick C. Investigators present latest findings on Hong Kong bird flu to the FDA. JAMA 1998, 279, 643-4.
McManus J. Questions remain as Hong KongÕs avian flu crisis continues. Brit Med J 1998, 316, 91.
Vogel U. Sequence offers clues to deadly flu. Science 1998, 279:324.
Casadevall A,Scharff MD Return to the past: the case for antibody-based theraties in infectious diseases.. Clinical Infectious Diseases 1995, 21, 150-61.
Wawrzynezak EJ Antibody Therapy. Oxford, UK: BIOS Science Publishers Limited, 1995, p9-10.
Burnie JP, Matthews RC. The renaissance of antibody therapy. J. Antimicrobial Chemotherapy 1998, 41, 3 19-322.
Klobasa F, Habe F, Werhahn E. Berl Munch Tierarztl The absorption of colostrum immunoglobulins in newborn piglets. II. Effect of water or glucose solutions on the permeability of the newborn intestine] Wochenschr 1991, 104, 3741.
Petschow BW, Talbott RD. J Pediatr Reduction in virus-neutralizing activity of a bovine colostrum immunoglobulin concentrate by gastric acid and digestive enzymes. Gastroenterol Nutr.1994,19,228-35.
Wawrzynezak EJ Antibody Therapy. Oxford, UK BIOS Scientific Publications Limited,1995, p32.
Rump JA. Arndt R, Arbold A, Bendick C.Dichtelmuller H, Franfe M, Helm EB, Jager H, Kampmann B, Kolb P. et al. Treatment of diarrhea in human immunodeficiency vieus-infected patients with inimunoglobulins from bovine colostrum. Clin Investig 1992, 70, 588-94.
Kirkpatrick CH. Transfer factors: identification of conserved sequences in transfer factor molecules. Mol Med 2000 Apr;6(4):332-41
Kirkpatrick CH. Activities and characteristics of transfer factors. Biotherapy 1996;9(1-3):13-6
Wong VG, Kirkpatrick CH. Immunologic reconstitution in a patient with keratoconjunctivitis, superficial candidiasis and hypoparathyroidism: the role of immunocompetent lymphocyte transfusion and transfer factor. Trans Am Ophthalmol Soc 1973;71:254-67; discussion 267-71
Alvarez-Thull L, Kirkpatrick CH.Profiles of cytokine production in recipients of transfer factors. Biotherapy 1996;9(1-3):55-9
Rozzo SJ, Kirkpatrick CH. Purification of transfer factors. Mol Immunol 1992 Feb;29(2):167-82
Kirkpatrick CH. Transfer factor. J Allergy Clin Immunol 1988 May;81(5 Pt 1):803-13
Pizza G, De Vinci C, Fornarola V, Palareti A, Baricordi O, Viza D.In vitro studies during long-term oral administration of specific transfer factor. Biotherapy 1996;9(1-3):175-85
Pilotti V, Mastrorilli M, Pizza G, De Vinci C, Busutti L, Palareti A, Gozzetti G, Cavallari A. Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy. Biotherapy 1996;9(1-3):117-21
Transfer factor with anti-EBV activity as an adjuvant therapy for nasopharyngeal carcinoma: a pilot study. Biotherapy 1996;9(1-3):109-15
Ablashi DV, Levine PH, De Vinci C, Whitman JE Jr, Pizza G, Viza D. Use of anti HHV-6 transfer factor for the treatment of two patients with chronic fatigue syndrome (CFS). Two case reports. Advanced Biotechnologies Inc., Columbia, MD 21046, USA Biotherapy 1996;9(1-3):81-6
Orally administered HSV-specific transfer factor (TF) prevents genital or labial herpes relapses. Biotherapy 1996;9(1-3):67-72
D. Preliminary observations using HIV-specific transfer factor in AIDS. Biotherapy 1996;9(1-3):41-7
Pizza G, De Vinci C, Fudenberg HH. Transfer factor in malignancy. Prog Drug Res 1994;42:401-21
Neequaye J, Viza D, Pizza G, Levine PH, De Vinci C, Ablashi DV, Biggar RJ, Nkrumah FK. Specific transfer factor with activity against Epstein-Barr virus reduces late relapse in endemic Burkitt's lymphoma.Anticancer Res 1990 Sep-Oct;10(5A):1183-7
Kirkpatrick CH. Structural nature and functions of transfer factors. Ann N Y Acad Sci 1993 Jun 23;685:362-8
De Vinci C, Pizza G, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G, Romagnoli P, Dragoni E, LoConte G, Riolo U, Masi M, Severini G, Fornarola V, Viza D. Use of transfer factor for the treatment of recurrent non-bacterial female cystitis (NBRC): a preliminary report. Biotherapy 1996;9(1-3):133-8
Grimm EA et al Lymphokine-activated killer cells. Induction and function. Annals of the New York Academy of Science 532: 380-6 (1988)
Hiserodt JC Lymphokine-activated killer cells: biology and relevance to disease. Cancer Investigations 11: 420-39 (1993)
Lindemann A et al Lymphokine activated killer cells. Blut 59: 375-84 (1989)
Melief CJ Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Advances in Cancer Research 58: 143-75 (1992)
Palmer PA et al Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. European Journal of Cancer 28A: 1038-44 (1992)
Young JDE and Liu CC Multiple mechanisms of lymphocyte-mediated killing Immunology Today 9: 140-4 (1988)
Ballas ZK and Rasmussen W Lymphokine-activated killer cells. VII. IL4 induces an NK1.1+CD8 alpha+beta- TCR-alpha beta B220+ lymphokine-activated killer subset. Journal of Immunology 150: 17-30 (1993)
Basse P et al Tissue distribution of adoptively transferred adherent lymphokine-activated killer cells assessed by different cell labels. Cancer Immunology Immunother. 34: 221-7 (1992)
Caligiuri MA et al Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. Journal of Clin. Oncol. 9: 2110-9 (1991)
Clayman GL et al Immunomodulation of the induction phase of lymphokine-activated killer activity by acute phase proteins. Otolaryngol. Head Neck Surg. 105: 26-34 (1991);
Colborn D et al Expansion of lymphokine-activated killer cells for clinical use utilizing a novel culture device Journal of Immunological Methods 119: 247-54 (1989)
Crump III WL et al Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells. Cancer Research 49: 149-53 (1989); Echarti C and Maurer HR Lymphokine-activated killer cells: determination of their tumor cytolytic capacity by a clonogenic microassay using agar capillaries Journal of Immunological Methods 143: 41-7 (1991)
Ettinghausen SE et al Haematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood 69: 1654-60 (1987)
Finkelstein DM and Miller RG Effect of culture media on lymphokine-activated killer effector phenotype and lytic capacity. Cancer Immunology Immunother. 33: 103-8 (1991)
Fujimoto T et al Evaluation of basic procedures for adoptive immunotherapy for gastric cancer. Biotherapy 5: 153-63 (1992)
Galandrini R et al Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity. European Journal of Immunology 22: 2047-53 (1992)
Gambacorti-Passerini C et al A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer. Journal of Immunother. 13: 43-8 (1993)
Geller RL et al Generation of lymphokine-activated killer activity in T cells: Possible regulatory circuits. Journal of Immunology 146: 3280-8 (1991)
Grimm EA et al TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity. Cancer Immunology Immunother. 27: 53-8 (1988)
Gunji Y et al Fibrin formation inhibits the in vitro cytotoxic activity of human natural and lymphokine-activated killer cells. Blood Coagul. Fibrinolysis. 1: 663-72 (1990);
Hank JA et al In vivo induction of the lymphokine-activated killer phenomenon: interleukin-2 dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin-2. Cancer Research 48: 1965-71 (1988)
Herrmann GG et al LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines. Nat. Immun.
11: 7-16 (1992)
Iho S et al Characteristics of interleukin-6-enhanced lymphokine-activated killer cell function. Cellular Immunology 135: 66-77 (1991)
Kasid A et al Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. Journal of Immunology 141: 690-8 (1988) Kato K et al Augmentation by tumor necrosis factor alpha of the systemic therapeutic effect of lymphokine-activated killer cells in adoptive immunotherapy of murine tumor. Japanese Journal of Cancer Research 82: 464-9 (1991)
Lazenby AW et al IL1 synergy with IL2 in the generation of lymphokine activated killer cells is mediated by TNF-alpha and beta lymphotoxin Cytokine 4: 479-87 (1992);
Lieberman MD et al Enhancement of interleukin-2 immunotherapy with L-arginine. Ann. Surg. 215: 157-65 (1992)
Lotze MT et al Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T cell growth factor. Cancer Research 41: 4420-5 (1981)
Lotze MT et al In vivo administration of purified human interleukin-2. II. half-life, immunological effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL2. Journal of Immunology 135: 2865-75 (1985)
Maas RA et al Mechanisms of tumor regression induced by low doses of interleukin-2. In vivo 5: 637-42 (1991)
Marumo K et al Enhancement of lymphokine-activated killer activity induction in vitro by interleukin-1 administered in patients with urological malignancies. Journal of Immunother.
11: 191-7 (1992)
Matossian-Rogers A et al Tumor necrosis factor-alpha enhances the cytolytic and cytostatic capacity of interleukin-2 activated killer cells. British Journal of Cancer 59: 573-7 (1989)
McKenzie RS et al Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2. Cancer Research 52: 6318-22 (1992)
Mehta S et al Lymphokine-activated effector cells: modulation of activity by cytokines. Lymphokine Cytokine Research 11: 73-7 (1992)
Melder RJ et al A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells. Cancer Research 48: 3461-9 (1988)
Miller JS et al Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors. Blood 77: 2389-95 (1991)
Mule JJ et al Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunology Immunother.
26: 95-100 (1988)
Murata M et al Development of a new culture system for human lymphokine-activated killer cells: Comparison with a conventional static culture method. Cytotechnology 7: 7583 (1991) Naume B et al Immunomagnetic isolation of NK and LAK cells Journal of Immunological Methods 136: 1-9 (1991)
Naume B et al Synergistic effects of interleukin 4 and interleukin 12 on NK cell proliferation Cytokine 5: 38-46 (1993)
Nishimura T et al Combination tumor-immunotherapy with recombinant tumor necrosis factor and recombinant interleukin-2 in mice. International Journal of Cancer 40: 255-61 (1987)
Ottonello L et al Suppression of lymphokine-activated killer (LAK) cell function by neutrophil polymorphonuclear leukocytes. Journal of Clin. Lab. Immunology 34: 37-40 (1991)
Owen-Schaub LB et al Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Research 48: 788-92 (1988)
Papamichail M and Baxevanis CN gamma-interferon enhances the cytotoxic activity of interleukin-2-induced peripheral blood lymphocyte (LAK) cells, tumor infiltrating lymphocytes (TIL), and effusion associated lymphocytes. Journal of Chemotherapy 4: 387-93 (1992)
Philips JH and Lanier LL Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. Journal of Experimental Medicine 164: 814-25 (1986)
Reiter Z and Taylor MW Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity. Cancer Research 53: 3555-60 (1993)
Schoof DD et al Survival characteristics of metastatic renal cell carcinoma patients treated with lymphokine-activated killer cells plus interleukin-2. Urology 41: 534-9 (1993)
Shimizu K et al A high density cell culture system for generation of human lymphokine-activated killer (LAK) cells for clinical use in adoptive immunotherapy. Journal of Clin. Lab. Immunology 32: 41-7 (1990)
Shimizu Y et al Proliferation and cytotoxicity of lectin-induced lymphokine-activated killer (LILAK) cells. Journal of Gastroenterology and Hepatology 6: 485-90 (1991);
Singh KP et al Protein A potentiates lymphokine-activated killer cell induction in normal and melanoma patient lymphocytes. Immunopharmacology and Immunotoxicology 14: 73-103 (1992)
Sondel PM et al Destruction of autologous human lymphocytes by interleukin 2activated cytotoxic cells. Journal of Immunology 137: 502-11 (1986) Tachibana I et al Generation of a small cell lung cancer variant resistant to lymphokine-activated killer (LAK) cells: association with resistance to a LAK cell-derived, cytostatic factor. Cancer Research 52: 3310-6 (1992)
Wersall P et al Simplified long term large scale production of highly active human LAK cells for therapy. Medical Oncology and Tumor Pharmacotherapy 7: 257-63 (1990);
Yannelli JR The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer Journal of Immunological Methods 139: 1-16 (1991)
Roth, J.A. “Enhancement of Neutrophil Function by Ultra filtered Bovine Whey”, J. Dairy Sci. 84:824-829, Vol. 84, No.4, 2001.
Gudmundsson GH, Agerberth B. J Immunol Methods 1999 Dec 17;232(1-2):45-54 Neutrophil antibacterial peptides, multifunctional effector molecules in the mammalian immune system.
Chaly YV, Paleolog EM, Kolesnikova TS, Tikhonov II, Petratchenko EV, Voitenok NN. Eur Cytokine Netw 2000 Jun;11(2):257-66 Neutrophil alpha-defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells.
Bateman A et al Granulins, a novel class of peptide from leukocytes. Biochemical and Biophysical Research Communications 173: 1161-8 (1990)
Belcourt DR et al Isolation and primary structure of the three major forms of granulinlike peptides from hematopoietic tissues of a teleost fish (Cyprinus carpio). Journal of Biological Chemistry 268(13): 9230-9237 (1993)
Belcourt DR et al Immunocytochemical localization of granulin-1 to mononuclear phagocytic cells of the teleost fish Cyprinus carpio and Carassius auratus. Journal of Leukocyte Biology 57(1): 94-100 (1995)
Bhandari V et al Isolation and sequence of the granulin precursor cDNA from human bone marrow reveals tandem cysteine-rich granulin domains. Proceedings of the National Academy of Science (USA) 89: 1715-9 (1992)
Bhandari V and Bateman A Structure and chromosomal location of the human granulin gene. Biochemical and Biophysical Research Communications 188: 57-63 (1992) Liau LM et al Identification of a human glioma-associated growth factor gene, granulin, using differential immuno-absorption. Cancer Research 60(5): 1353-60 (2000)
Sparro G et al Isolation and N-terminal sequence of multiple forms of granulins in human urine. Protein Expression and Purification 1997 Jul;10(2):169-74 (1997)
Trinh DP et al Epithelin/granulin growth factors: extracellular cofactors for HIV-1 and HIV-2 Tat proteins. Biochemical Biophysical Research Communications 256(2): 299306 (1999)
Zanocco-Marani T Biological activities and signaling pathways of the granulin/epithelin precursor. Cancer Research 1999 59(20): 5331-40 (1999)
Acha-Orbea H et al Inhibition of lymphocyte mediated cytotoxicity by perforin antisense oligonucleotides EMBO Journal 12: 3815-9 (1990)
Fink TM et al Human perforin (PRF1) maps to 10q22, a region that is syntenic with mouse chromosome 10. Genomics 13: 1300-2 (1992)
Hameed A et al Immunohistochemical identification of cytotoxic lymphocytes using human perforin monoclonal antibody. American Journal of Patholology 140: 1025-30 (1992)
Henkart PA Mechanisms of lymphocyte-mediated cytotoxicity. Annual Review of Immunology 3: 31-58 (1985)
Lichtenheld MG Structure and function of human perforin Nature (London) 335: 448-51 (1988)
Lichtenheld MG et al Structure of the human perforin gene: a simple gene organization with interesting potential regulatory sequences. Journal of Immunology 143: 4267-74 (1989)
Liu CC Identification and characterization of a pore-forming protein of human peripheral blood natural killer cells. Journal of Experimental Medicine 164: 2061-76 (1986)
Lowrey DM et al Isolation and characterization of cytotoxic granules from human lymphokine (interleukin 2) activated killer cells. Cancer Research 48: 4681-8 (1988)
Lu P et al Perforin expression in human peripheral blood mononuclear cells. Definition of an IL2-independent pathway of perforin induction in CD8 + T cells. Journal of Immunology
148: 3354-60 (1992)
Masson D and Tschopp J Isolation of a lytic, pore-forming protein (perforin) from cytolytic T lymphocytes. Journal of Biological Chemistry 260: 9069-72 (1985) Ojcius DM and Young JDE Cytolytic pore-forming proteins and peptides: is there a common structural motif Trends in Biochemical Sciences 16: 225-9 (1991)
Podack ER Molecular mechanisms of lymphocyte-mediated tumor cell lysis Immunology Today 6: 21-7 (1985)
Podack ER et al Structure, function and expression of murine and human perforin 1 (P1). Immunological Reviews 103: 203-11 (1988)
Podack ER et al Isolation and biochemical and functional characterization of perforin 1 from cytolytic T cell granules. Proceedings of the National Academy of Science (USA)
82: 8629-33 (1985)
Podack ER et al A central role of perforin in cytolysis? Annual Review of Immunology
9: 129-57 (1991)
Podack ER and Kupfer A T cell effector functions: mechanisms for delivery of cytotoxicity and help. Annual Review of Cell Biology 7: 479-504 (1991)
Shinkai Y et al Molecular cloning and chromosomal assignment of the human perforin (PFP) gene. Immunogenetics. 30: 452-7 (1989)
Smyth MJ et al IL2 and IL6 synergise to augment the pore-forming protein gene expression and cytotoxic potential of human peripheral blood T cells. Journal of Immunology 145: 1156-66 (1990)
Trapani JA et al Genomic organization of the mouse pore- forming protein (perforin) gene and localization to chromosome 10: similarities to and differences from C9. Journal of Experimental Medicine 171: 545-57 (1990)
Young JDE and Cohn ZA Cellular and humoral mechanisms of cytotoxicity: structural and functional analogies. Advances in Immunology 41: 269-332 (1987)
Young JDE et al Properties of a purified pore-forming protein (perforin 1) isolated from H2-restricted cytotoxic T cell granules. Journal of Experimental Medicine 164: 144-55 (1986)
Young JDE et al Purification and characterization of a cytolytic pore-forming protein from granules of cloned lymphocytes with natural killer activity. Cell 44: 849-59 (1986)
Zalman LS et al The cytolytic protein of human lymphocytes related to the ninth component (C9) of human complement: isolation from anti-CD3-activated peripheral blood mononuclear cells. Proceedings of the National Academy of Science (USA) 84: 2426-9 (1987)
Baggiolini M et al Human chemokines: an update. Annual Review of Immunology 15: 675-705 (1997)
Jahnz-Rozyk K Chemokines - New markers of inflammation. International Review of Allergology and Clinical Immunology 4(4): 143-149 (1998)
Luther SA and Cyster JG Chemokines as regulators of T cell differentiation. Nature Immunology 2(2): 102-7 (2001)
Mackay CR Chemokines: what chemokine is that? Current Biology 7(6): R384-386 (1997)
Mahalingam S et al Antiviral potential of chemokines.Bioessays 23(5): 428-35 (2001);
Miller MD and Krangel MS Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Critical Review of Immunology 12: 17-46 (1992)
Moser B et al Lymphocyte responses to chemokines. International Review of Immunology 16(3-4): 323-344 (1998)
Moser B and Loetscher P Lymphocyte traffic control by chemokines. Nature Immunology 2(2): 123-8 (2001)
Oppenheim JJ et al Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annual Review of Immunology 9: 617-648 (1991)
Proudfoot AE et al The strategy of blocking the chemokine system to combat disease. Immunological Reviews 177: 246-56 (2000)
Rossi D and Zlotnik A The biology of chemokines and their receptors. Annual Reviews of Immunology 2000; 18217-42 (2000)
Wang JM et al Chemokines and their role in tumor growth and metastasis Journal of Immunological Methods 220(1-2): 1-17 (1998)
Yoshie O et al Chemokines in immunity. Advances in Immunology 2001; 78: 57-110 (2001)
Zlotnik A et al Recent advances in chemokines and chemokine receptors. Critical Reviews of Immunology 19(1): 1-47 (1999)
Aizawa S et al Biological activities of tetrapeptide AcSDKP on hemopoietic cell binding to the stromal cell in vitro. Experimental Hematology 20: 896-899 (1992)
Deeg HJ et al In vivo radioprotective effect of AcSDKP on canine myelopoiesis. Annals of Hematology 74(3): 117-122 (1997)
Genevay MC et al The synthetic tetrapeptide AcSDKP protects cells that reconstitute long-term bone marrow stromal cultures from the effects of mafosfamide (Asta Z 7654). Experimental Hematology 24(1): 77-81 (1996)
Grillon C et al Involvement of thymosin beta 4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system. FEBS Letters 274: 30-34 (1990)
Grillon C et al Optimization of cell culture conditions for the evaluation of the biological activities of the tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro, a natural hemoregulatory factor. Growth Factors 9: 133-138 (1993)
Guigon M et al Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP. Experimental Hematology 18: 1112-1115 (1990)
Huang WQ and Wang QR Bone marrow endothelial cells secrete thymosin beta4 and AcSDKP. Experimental Hematology 2001 Jan;29(1):12-8 (2001)
Jackson JD et al Activity of acetyl-n-ser-asp-lys-pro (AcSDKP) on hematopoietic progenitor cells in short-term and long-term murine bone marrow cultures. Experimental Hematology 24(3): 475-481 (1996)
Jackson JD et al Activity of acetyl-Ser-Asp-Lys-Pro (AcSDKP) on human hematopoietic progenitor cells in short-term and long-term bone marrow cultures. Journal of Hematotherapy and Stem Cell Research 9(4):489-96 (2000)
Lenfant M et al Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proceedings of the National Academy of Science (USA)
86: 779-782 (1989)
Rousseau A et al The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. Journal of Biological Chemistry 270(8): 3656-3661 (1995)
Thierry J et al Synthesis and biological evaluation of analogues of the tetrapeptide NAcetyl-Ser-Asp-Lys-Pro (AcSDKP), an inhibitor of primitive haematopoietic cell proliferation. Journal of Peptide Science 7(5): 284-93 (2001)
Watanabe T et al In vivo haemoprotective activity of tetrapeptide AcSDKP combined with granulocyte-colony stimulating factor following sublethal irradiation. British Journal of Haematology 94(4): 619-627 (1996) Wierenga PK Purging of acute myeloid leukaemia cells from stem cell grafts by hyperthermia: enhancement of the therapeutic index by the tetrapeptide AcSDKP and the alkyl-lysophospholipid ET-18-OCH(3). British Journal of Haematology 111(4):1145-52 (2000)
Benjannet S et al PC1 and PC2 are proprotein convertases capable of cleaving proopiomelanocortin at distinct pairs of basic residues. Proceedings of the National Academy of Science (USA) 88: 3564-8 (1991)
Chang ACY et al Structural organization of human genomic DNA encoding the proopiomelanocortin peptide. Proceedings of the National Academy of Science (USA) 77: 4890-4894 (1980)
Cochet M et al Characterization of the structural gene and putative 5-prime-regulatory sequences for human proopiomelanocortin Nature (London) 297: 335-339 (1982);
Chretien M et al From beta-lipotropin to beta-endorphin and 'pro-opio-melanocortin.' Canadian Journal of Biochemistry 57: 1111-1121 (1979)
Eipper BA and Mains RE Structure and biosynthesis of pro- adrenocorticotropin-endorphin and related peptides. Endocrine Rev. 1: 1-27 (1980)
Jones MT and Gilham B Factors involved in the regulation of adrenocorticotropic hormone/b lipotropic hormone. Physiol. Rev. 68: 743-818 (1988)
Kraus J et al Regulatory elements of the human proopiomelanocortin gene promoter. DNA and Cell Biology 12: 527-36 (1993)
Loh VP et al Intracellular trafficking and processing of pro-opiomelanocortin. Cell Biophys. 19: 73-83 (1991)
Mains RE and Eipper BA The tissue-specific processing of pro-ACTH/endorphin: Recent advances and unsolved problems. Trends Endocrinol. Metab. 1: 388-94 (1990);
Monig H et al Structure of the POMC promoter region in pituitary and extrapituitary ACTH producing tumors. Experimental Clin. Endocrinol. 101: 36-8 (1993)
Nakai Y et al Molecular mechanisms of glucocorticoid inhibition of human proopiomelanocortin gene transcription. Journal of Steroid Biochemistry and Molecular Biology 40: 301-6 (1991)
Riegel AT et al Proopiomelanocortin gene promoter elements required for constitutive and glucocorticoid-repressed transcription. Molecular Endocrinology 5: 1973-82 (1991); Roberts JL et al Regulation of pituitary proopiomelanocortin gene expression. In: Herz A (edt) Handbook of Experimental Pharmacology 104/I: 347-77, Springer, Berlin (1993);
Sacerdote P et al Pharmacological modulation of neuropeptides in peripheral mononuclear cells. Journal of Neuroimmunol. 32: 35-41 (1991)
Sharp B and Linner K What do we know about the expression of proopiomelanocortin transcripts and related peptides in lymphoid tissue? Endocrinology 133: 1921A-21B (1993)
Therrien M and Drouin J Molecular determinants for cell specificity and glucocorticoid repression of the proopiomelanocortin gene. Annals of the New York Academy of Science
680: 663-71 (1993)
Van Woudenberg AD et al Analysis of proopiomelanocortin (POMC) messenger ribonucleic acid and POMC-derived peptides in human peripheral blood mononuclear cells: no evidence for a lymphocyte-derived POMC system. Endocrinology 133: 1922-33 (1993)
Alvarez-Mon M et al ACTH:A potential role for adrenocorticotropin in regulating human B lymphocyte functions. Journal of Immunology 135: 3823-6 (1985)
Bennett HPJ et al Confirmation of the 1-20 amino acid sequence of human adrenocorticotropin. Biochemical Journal 133: 11-13 (1973)
Brooks KH Adrenocorticotropin (ACTH) functions as a late-acting B cell growth factor and synergizes with interleukin 5. Journal of Mol. Cell. Immunology 4: 327-35 (1990);
Carr DJJ et al Corticotropin-releasing hormone augments natural killer cell activity through a naloxone-sensitive pathway. Journal of Neuroimmunol. 28: 53-61 (1990);
Gatti G et al Interplay in vitro between ACTH, beta-endorphin, and glucocorticoids in the modulation of spontaneous and lymphokine-inducible human natural killer (NK) cell activity. Brain Behav. Immunology 7: 16-28 (1993)
Johnson HM et al Regulation of lymphokine gamma-interferon production by corticotropin. Journal of Immunology 132: 246-50 (1984)
Karanth S and McCann SM Anterior pituitary hormone control by interleukin 2. Proceedings of the National Academy of Science (USA) 88: 2961-5 (1991)
McGillis JP et al Stimulation of rat B lymphocyte proliferation by corticotropin-releasing factor. Journal of Neuroscience Research 23: 346-52 (1989)
Lee TH et al On the structure of human corticotropin (adrenocorticotropic hormone). Journal of Biological Chemistry 236: 2970-2974 (1961)
McGlone JJ et al Adrenocorticotropin stimulates natural killer cell activity. Endocrinology 129: 1653-8 (1991) Mesiano S et al Basic fibroblast growth factor expression is regulated by corticotropin in the human fetal adrenal: A model for adrenal growth regulation. Proceedings of the National Academy of Science (USA) 88: 5428-32 (1991)
Ohgo S et al Interleukin-1 (IL1) stimulates the release of corticotropin-releasing factor (CRF) from superfused rat hypothalamo-neurohypophyseal complexes (HNC) independently of the histaminergic mechanism. Brain Research 558: 217-23 (1991);
Owens MJ and Nemeroff CB Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. 43: 425-73 (1991)
Plotsky PM et al Central activin administration modulates corticotropin-releasing hormone and adrenocorticotropin secretion. Endocrinology 128: 2520-5 (1991)
Smith EM et al Corticotropin releasing factor induction of leukocyte-derived immunoreactive ACTH and endorphins Nature (London) 322: 881-2 (1986)
Singh VK Stimulatory effect of corticotropin-releasing neurohormone on human lymphocyte proliferation and interleukin 2 receptor expression. Journal of Neurimmunol.
23: 257-62 (1989)
Suda T et al Interleukin-1 stimulates corticotropin-releasing factor gene expression in rat hypothalamus. Endocrinology 126: 1223-8 (1990)
Webster EL et al Upregulation of interleukin-1 receptors in mouse AtT-20 pituitary tumor cells following treatment with corticotropin-releasing factor. Endocrinology 129: 2796-8 (1991)
Yamashiro D and Li CH Adrenocorticotropins. 44. Total synthesis of the human hormone by the solid-phase method. Journal of Am. Chem. Soc. 95: 1310-1315 (1973)
MSH: Brown SL et al Suppression of T lymphocyte chemotactic factor production by the opioid peptides beta-endorphin and Met-enkephalin. Journal of Immunology 134: 3384-90 (1985)
Harris JI Structure of a melanocyte-stimulating hormone from the human pituitary gland Nature (London) 184: 167-169 (1959)
Jegou S et al Regulation of alpha-melanocyte-stimulating hormone release from hypothalamic neurons. Annals of the New York Academy of Science 680: 260-78 (1993)
Leu SJC and Singh VK Modulation of natural killer cell-mediated lysis by corticotropin-releasing neurohormone. Journal of Neuroimmunol. 33: 253-60 (1991);
Martin LW et al Neuropeptide alpha-MSH antagonizes IL6- and TNF-induced fever. Peptides 12: 297-9 (1991)
Mason MJ and Van Epps DE Modulation of interleukin 1, tumor necrosis factor, and C5a-mediated neutrophil migration by alpha-melanocyte stimulating hormone (MSH). Journal of Immunology 142: 1646-51 (1989) Nordlund JJ alpha-Melanocyte-stimulating hormone: A ubiquitous cytokine with pigmenting effects. JAMA 266: 2753-4 (1991)
Smith EM et al Immunosuppressive effects of corticotropin and melanotropin and their possible significance in human immunodeficiency virus infection. Proceedings of the National Academy of Science (USA) 89: 782-6 (1992)
Taylor AW et al Identification of alpha-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. Curr. Eye Research 11: 1199-206 (1992);
Uehara Y et al Carboxyl-terminal tripeptide of alpha-melanocyte-stimulating hormone antagonizes interleukin-1-induced anorexia. European Journal of Pharmacol. 220: 119-22 (1992)
Villar M et al Central and peripheral actions of alpha-MSH in the thermoregulation of rats. Peptides 12: 1441-3 (1991)
Endorphins: Chiappelli F et al Differential effect of beta-endorphin on three human cytotoxic cell populations. International Journal of Immunopharmacology 13: 291-7 (1991)
Davis TP and Crowell SL beta-Endorphin is metabolized in vitro by human small lung cancer to gamma-Endorphin which stimulates clonal growth. In: Moody TW (edt), Growth Factors, Peptides and Receptors, pp 389-400, Plenum Press New York (1993);
Faith RE et al Neuroimmunomodulation with enkephalins: enhancement of human natural killer (NK) cell activity in vitro. Clin. Immunology Immunopharmacol. 31: 412-8 (1984)
Garcia I et al beta-endorphin inhibits interleukin-2 release and expression of interleukin2 receptors in concanavalin A-stimulated splenic lymphocytes. Lymphokine Cytokine Research 11: 339-45 (1992)
Gilman SC et al beta-Endorphin enhances lymphocyte proliferative responses. Proceedings of the National Academy of Science (USA) 79: 4226-30 (1982)
Gilmore W and Weiner LP beta-endorphin enhances interleukin (IL2) production in murine lymphocytes. Journal of Neuroimmunol. 18: 125-8 (1988)
Gilmore W et al The enhancement of polyclonal T cell proliferation by beta-endorphin. Brain Research Bull. 24: 687-92 (1990)
Hemmick LM and Bidlack JM Endorphin peptides enhance mitogen-induced T cell proliferation which has been suppressed by prostaglandins. Advances in Experimental Medicine and Biology 288: 211-4 (1991)
Hemmick L and Bidlack JM beta-Endorphin stimulates rat T lymphocyte proliferation. Journal of Neuroimmunol. 29: 239-48 (1990) Kay N et al Interaction between endogenous opioids and IL2 on PHA-stimulated human lymphocytes. Immunology 70: 485-91 (1990)
Mathews PM et al Enhancement of natural cytotoxicity by beta-endorphin. Journal of Immunology 13: 1658-62 (1983)
McCain HW et al beta-Endorphin modulates human immunity via non-opiate receptor mechanisms. Life Sci. 31: 1619-24 (1982)
Morgano A et al Expression of HLA class II antigens and proliferative capacity in autologous mixed lymphocyte reactions of human T lymphocytes exposed in vitro to alpha-endorphin. Brain Behav. Immun. 3: 214-22 (1989)
Oleson DR and Johnson DR Regulation of human natural cytotoxicity by enkephalins and selective opiate agonists. Brain Behav. Immunology 2: 171-86 (1988)
Peterson PK et al Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells. Journal of Clinical Investigation 80: 824-31 (1987)
Van den Bergh P et al Two opposing modes of action of beta-endorphin on lymphocyte function. Immunology 72: 537-43 (1991)
Van den Bergh P et al Identification of two moieties of beta-endorphin with opposing effects on rat T-cell proliferation. Immunology 79: 18-23 (1993)
Van Epps DE and Saland L beta-Endorphin and Met-enkephalin stimulate human peripheral blood mononuclear cell chemotaxis. Journal of Immunology 132: 3046-53 (1984)
Helseth A et al Transgenic mice that develop pituitary tumors. A model for Cushing's disease. American Journal of Patholology 140: 1071-80 (1992)
Muglia LJ et al Expression of the mouse corticotropin-releasing hormone gene in vivo and targeted inactivation in embryonic stem cells. Journal of Clinical Investigation 93: 2066-72 (1994)
Stenzel-Poore MP Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology 130: 3378-86 (1992)
Tremblay Y et al Pituitary-specific expression and glucocorticoid regulation of a proopiomelanocortin fusion gene in transgenic mice. Proceedings of the National Academy of Science (USA) 85: 8890-4 (1988)
Almeida RP et al Complementary DNA sequence of human neutrophil azurocidin, an antibiotic with extensive homology to serine proteases. Biochemical and Biophysical Research Communications 177: 688-95 (1991)
Campanelli D et al Azurocidin and a homologous serine protease from neutrophils: differential antimicrobial and proteolytic properties. Journal of Clinical Investigation 85: 904-15 (1990)
Heinzelmann M et al Endocytosis of heparin-binding protein (CAP37) is essential for the enhancement of lipopolysaccharide-induced TNF-alpha production in human monocytes. Journal of Immunology 162(7): 4240-5 (1999)
Morgan JG et al Cloning of the cDNA for the serine protease homologue CAP37/azurocidin, a microbicidal and chemotactic protein from human granulocytes. Journal of Immunology 147: 3210-4 (1991)
Pereira HA et al CAP37, a human neutrophil-derived chemotactic factor with monocyte specific activity. Journal of Clinical Investigation 85: 1468-76 (1990)
Pohl J et al Amino acid sequence of CAP37, a human neutrophil granule-derived antibacterial and monocyte-specific chemotactic glycoprotein structurally similar to neutrophil elastase. FEBS Letters 272: 200-4 (1990)
Rasmussen PB et al Characterization of recombinant human hbp/cap37/azurocidin, a pleiotropic mediator of inflammation enhancing lps induced cytokine release from monocytes. FEBS Letters 390(1): 109-112 (1996)
Wilde CG et al Characterization of two azurophil granule proteases with active-site homology to neutrophil elastase. Journal of Biological Chemistry 265: 2038-41 (1990);
Zimmer M et al Three human elastase-like genes coordinately expressed in the myelomonocyte lineage are organized as a single genetic locus on 19pter. Proceedings of the National Academy of Science (USA) 89: 8215-9 (1992)
Bevis CL and Zasloff M Peptides from frog skin. Annual Review of Biochemistry 59: 395-414 (1990)
Castiglione R de and Gozzini L Non-mammalian peptides: structure determination synthesis, and biological activity. Chimicaoggi April 1991, pp. 9-15
Rozengurt E Neuropeptides as cellular growth factors: Role of multiple signaling pathways. European Journal of Clinical Investigation 21: 123-34 (1991) Schüller HM Receptor-mediated mitogenic signals and lung cancer. Cancer Cells 3: 496503 (1991)
Woll P and Rozengurt E Neuropeptides as growth regulators. British Medical Bulletin
45: 492-505 (1989)
Lévesque A et al Synthesis of bombesin analogs by the Fmoc method. Advances in Cancer Research 11: 2215-22 (1991)
Shipp MA et al CD10/neutral endopeptidase 24. 11 hydrolyses bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proceedings of the National Academy of Science (USA) 88: 10662-6 (1991)
Battey J and Wada E Two distinct receptor subtypes for mammalian bombesin-like peptides. Trends in Neurological Sciences 14: 524-8 (1991)
Battey J et al Molecular cloning of the bombesin/gastrin-releasing peptide precursor from Swiss 3T3 cells. Proceedings of the National Academy of Science (USA) 88: 395-9 (1991)
Corjay MH et al Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. Journal of Biological Chemistry 266: 18771-9 (1991);
Houben H and Denef C Bombesin receptor antagonists and their use in the evaluation of paracrine and autocrine intercellular communication. Front. Horm. Res. 19: 176-95 (1991)
Kane MA et al Isolation of the bombesin/gastrin-releasing peptide receptor from human small cell lung carcinoma NCI-H345 cells. Journal of Biological Chemistry 266: 9486-93 (1991)
Rozengurt E and Sinnett-Smith J Bombesin stimulation of fibroblast mitogenesis: specific receptors, signal transduction, and early events. Philosophical Transactions of the Royal Society London. Biol. 327: 209-21 (1990)
Rozengurt E et al Mitogenic signaling through the bombesin receptor: Role of a guanine nucleotide regulatory protein. JCS13: s43-s56 (1990)
Shapira H et al Distinguishing bombesin receptor subtypes using the oocyte assay. Biochemical and Biophysical Research Communications 176: 79-86 (1991)
Zachary I and Rozengurt E High affinity receptors for peptides of the bombesin family in Swiss 3T3 cells. Proceedings of the National Academy of Science (USA) 82: 7616-20 (1985)
Zachary I et al Bombesin, vasopressin, and endothelin rapidly stimulate tyrosine phosphorylation in intact Swiss 3T3 cells. Proceedings of the National Academy of Science (USA) 88: 4577-81 (1991) Carney DN et al Bombesin is an autocrine growth factor for human small cell lung cancer cell lines. Proc. Am. Fed. Clin. Res. 31: 404 (1983)
Cuttitta F et al Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer Nature (London) 316: 823-6 (1985)
Endo T et al Bombesin and bradykinin increase inositol phosphates and cytosolic free Ca2+, and stimulate DNA synthesis in human endometrial stromal cells. Journal of Endocrinology 131: 313-8 (1991)
Isonishi S et al Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha. Journal of Clinical Investigation 90: 1436-42 (1992)
Johnson TC and Sharifi BG Abrogation of the mitogenic activity of bombesin by a cell surface sialoglycopeptide growth inhibitor. Biochemical and Biophysical Research Communications 161: 468-74 (1989)
Lemaire I Bombesin-related peptides modulate interleukin-1 production by alveolar macrophages. Neuropeptides 20: 217-23 (1991)
Narayan S et al A potent bombesin receptor antagonist inhibits bombesin-stimulated growth of mouse colon cancer cells in vitro: absence of autocrine effects. Cell Growth and Differentiation 3: 111-8 (1992)
Nelson J et al Bombesin stimulates proliferation of human breast cancer cells in culture. British Journal of Cancer 63: 933-6 (1991)
Radulovic S et al Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095). Cancer Research 51: 6006-9 (1991)
Rozengurt E and Sinnett-Smith J Bombesin stimulation of DNA synthesis and cell division of Swiss 3T3 cells. Proceedings of the National Academy of Science (USA) 80: 2936-40 (1983)
Schrey MP et al Bombesin